Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months

Eribulin is a non-taxane microtubule inhibitor approved for the treatment of metastatic breast carcinoma after two prior chemotherapeutic regimens. We report a patient with extended progression-free survival (PFS) of more than 57 months with metastatic breast carcinoma treated with eribulin in the t...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cureus
Main Authors: Manthri, Sukesh, Sharma, Purva, Mejbel, Haider Atheer, Singal, Sakshi, Jaishankar, Devapiran
Format: Artigo
Sprog:Inglês
Udgivet: Cureus 2020
Fag:
Internal Medicine
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7075509/
https://ncbi.nlm.nih.gov/pubmed/32201658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.6980
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker